Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* individuals who are 19-65 years of age inclusive and who, after the nature of the study has been explained have provided written informed consent~* individuals who are available for all visits and telephone calls scheduled for the study;~* individuals who are in good health~Exclusion Criteria:~* individuals with a previous or suspected disease caused by N. meningitidis~* individuals with previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s)~* individuals with previous or suspected disease caused by N. meningitidis~* individuals with any serious acute, chronic or progressive disease~* individuals who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Novartis MenACWY Vaccine (19 to 55 Years) (Type: EXPERIMENTAL): Novartis meningococcal ACWY conjugate vaccine administered to subjects 19 years to 55 years
- Licensed polysaccharide vaccine (Type: ACTIVE_COMPARATOR): Licensed meningococcal ACWY polysaccharide vaccine
- Licensed Conjugate Vaccine (Type: ACTIVE_COMPARATOR): Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
- Novartis MenACWY Vaccine (56 to 65 Years) (Type: EXPERIMENTAL): Novartis meningococcal ACWY conjugate vaccine administered to subjects 56 years to 65 years

Based on this trial design, predict the completion outcome and termination type (if applicable).